辛迪制药

最新新闻

• 评级变动
  Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• 评级变动
  Jefferies Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37
  \u5e02\u573a\u8d44\u8baf · 2026/5/2
• 评级变动
  Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $46
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• 公司公告
  Syndax Pharmaceuticals: Syndax Pharmaceuticals, Inc. - Flex Position Consolidation Option Symbol: 1SNDX
  OCC · 2025/8/12
• 评级变动
  H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• H.C. Wainwright Sticks to Its Buy Rating for Syndax Pharmaceuticals (SNDX)
  TipRanks · 2026/9/22
• 评级变动
  TD Cowen Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• 评级变动
  Guggenheim Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $31
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• 评级变动
  A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $29 to $40
  \u5e02\u573a\u8d44\u8baf · 2026/5/1
• H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $38
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $57
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $26 to $57
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $46
  \u5e02\u573a\u8d44\u8baf · 2026/5/4
• 评级变动
  Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $37
  \u5e02\u573a\u8d44\u8baf · 2026/7/20
• UBS Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $33
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 评级变动
  J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $26
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  UBS Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37
  \u5e02\u573a\u8d44\u8baf · 2026/5/13
• 评级变动
  BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/7/22

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。